Tuberculosis vaccine development at a divide

Current Opinion in Pulmonary Medicine

Volumn 20, Issue 3, 2014, Pages 294-300

  Kaufmann, Stefan H E ^a  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

Author keywords

replacement prime vaccine; subunit booster vaccine; therapeutic vaccine; tuberculosis

Indexed keywords

BCG VACCINE; RECOMBINANT VACCINE;

ADENOVIRUS; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); COWPOX VIRUS; DRUG EFFICACY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; EXTRAPULMONARY TUBERCULOSIS; HUMAN; IMMUNOGENICITY; LATENT TUBERCULOSIS; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; TUBERCULOSIS; VACCINATION; DRUG DESIGN; FEMALE; IMMUNIZATION; IMMUNOLOGY; MALE; TRENDS;

BCG VACCINE; DRUG DESIGN; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; MALE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINATION; VACCINES, SYNTHETIC;

EID: 84897583097     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000041     Document Type: Review

References (70)

1. Chen K, Kolls JK. T cell-mediated host immune defenses in the lung. Annu Rev Immunol 2013; 31:605-633.
2. Lozano R, NaghaviM, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study. Lancet 2012; 380:2095-2128.
3. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994; 271:698-702.
4. WHO Global. Tuberculosis Report. Geneva: WHO Press; 2013.
5. Diel R, Vandeputte J, de VG, et al. Costs of tuberculosis disease in the EU: a systematic analysis and cost calculation. Eur Respir J 2014; 43:554-565.
6. Stop TB Partnership, WHO. The Global Plan to Stop TB 2011-2015; 2011.
7. Kaufmann SHE, Hussey G, Lambert PH. New vaccines for tuberculosis. Lancet 2010; 375:85-94.
8. Kaufmann SH. Tuberculosis vaccines: time to think about the next generation. Semin Immunol 2013; 25:172-181.
9. Frick M. The TB vaccines pipeline: where are we going, where have we been? [2013 Pipeline Report], 263-283. London: HIV i-Base and Treatment Action Group; 2013.
10. Ottenhoff THM, Kaufmann SHE. Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog 2012; 8:e1002607.
11. Lawn SD, Zumla AI. Tuberculosis. Lancet 2011; 378:57-72.
12. Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. N Engl J Med 2013; 368:745-755.
13. Collins HL, Kaufmann SHE. The many faces of host responses to tuberculosis. Immunology 2001; 103:1-9.
14. O'Garra A, Redford PS, McNab FW, et al. The immune response in tuberculosis. Annu Rev Immunol 2013; 31:475-527.
15. Achkar JM, Casadevall A. Antibody-mediated immunity against tuberculosis: implications for vaccine development. Cell Host Microbe 2013; 13:250-262.
16. Prabowo SA, Groschel MI, Schmidt ED, et al. Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines. Med Microbiol Immunol 2013; 202:95-104.
17. Abel B, Tameris M, Mansoor N, et al. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am J Respir Crit Care Med 2010; 181:1407-1417.
18. McShane H, Pathan AA, Sander CR, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004; 10:1240-1244.
19. Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy ofMVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013; 381:1021-1028.
20. Mittrucker HW, Steinhoff U, Kohler A, et al. Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis. Proc Natl Acad Sci USA 2007; 104:12434-12439.
21. Kagina BM, Abel B, Scriba TJ, et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am J Respir Crit Care Med 2010; 182:1073-1079.
22. Weiner J III, Kaufmann SHE. Recent advances towards tuberculosis control: vaccines and biomarkers. J Intern Med 2014. doi:10.1111/joim.12212.
23. Beverley P. TB vaccine failure was predictable. Nature 2013; 503:469.
24. Scriba TJ, Tameris M, Smit E, et al. A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV-and/or Mycobacterium tuberculosis-infected adults. Am J Respir Crit Care Med 2012; 185:769-778.
25. Dintwe OB, Day CL, Smit E, et al. Heterologous vaccination against human tuberculosis modulates antigen-specific CD4+ T-cell function. Eur J Immunol 2013; 43:2409-2420.
26. Rowland R, Pathan AA, Satti I, et al. Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial. Hum Vaccin Immunother 2013; 9:50-62.
27. Frahm N, DeCamp AC, Friedrich DP, et al. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest 2012; 122:359-367.
28. Hammer SM, Sobieszczyk ME, Janes H, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 2013; 369:2083-2092.
29. Haynes BF, McElrath MJ. Progress in HIV-1 vaccine development. Curr Opin HIV AIDS 2013; 8:326-332.
30. Radosevic K, Wieland CW, Rodriguez A, et al. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect Immun 2007; 75:4105-4115.
31. Smaill F, Jeyanathan M, Smieja M, et al. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting antiadenovirus immunity. Sci Transl Med 2013; 5:205ra134.
32. Hoft DF, Blazevic A, Stanley J, et al. A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity. Vaccine 2012; 30:2098-2108.
33. Day CL, Tameris M, Mansoor N, et al. Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults. Am J Respir Crit Care Med 2013; 188:492-502.
34. Leroux-Roels I, Leroux-Roels G, Ofori-Anyinam O, et al. Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults. Clin Vaccine Immunol 2010; 17:1763-1771.
35. Leroux-Roels I, Forgus S, De BF, et al. Improved CD4(+) T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine 2013; 31:2196-2206.
36. Montoya J, Solon JA, Cunanan SR, et al. A randomized, controlled dosefinding phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults. J Clin Immunol 2013; 33:1360-1375.
37. Spertini F, Audran R, Lurati F, et al. The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study. Tuberculosis (Edinb) 2013; 93:179-188.
38. van Dissel JT, Arend SM, Prins C, et al. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. Vaccine 2010; 28:3571-3581.
39. van Dissel JT, Soonawala D, Joosten SA, et al. Ag85B-ESAT-6 adjuvanted with IC31(R) promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection. Vaccine 2011; 29:2100-2109.
40. Billeskov R, Elvang TT, Andersen PL, Dietrich J. The HyVac4 subunit vaccine efficiently boosts BCG-primed antimycobacterial protective immunity. PLoS One 2012; 7:e39909.
41. Gengenbacher M, Kaufmann SHE. Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol Rev 2012; 36:514-532.
42. Diel R, Goletti D, Ferrara G, et al. Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011; 37:88-99.
43. Dietrich J, Aagaard C, Leah R, et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol 2005; 174:6332-6339.
44. Aagaard C, Hoang T, Dietrich J, et al. A multistage tuberculosis vaccine that confers efficient protection pre and postexposure. Nat Med 2011; 17:189-194.
45. Govender L, Abel B, Hughes EJ, et al. Higher human CD4 T cell response to novel Mycobacterium tuberculosis latency associated antigens Rv2660 and Rv2659 in latent infection compared with tuberculosis disease. Vaccine 2010; 29:51-57.
46. Houghton J, Cortes T, Schubert O, et al. A small RNA encoded in the Rv2660c locus of Mycobacterium tuberculosis is induced during starvation and infection. PLoS One 2013; 8:e80047.
47. Bertholet S, Ireton GC, Ordway DJ, et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med 2010; 2:53ra74.
48. Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med 2013; 19:1597-1608.
49. Christensen D, Foged C, Rosenkrands I, et al. CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations. Int J Pharm 2010; 390:19-24.
50. Lingnau K, Riedl K, von GA. IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems. Expert Rev Vaccines 2007; 6:741-746.
51. Kaufmann SH, Gengenbacher M. Recombinant live vaccine candidates against tuberculosis. Curr Opin Biotechnol 2012; 23:900-907.
52. Grode L, Seiler P, Baumann S, et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Gué rin mutants that secrete listeriolysin. J Clin Invest 2005; 115:2472-2479.
53. Grode L, Ganoza CA, Brohm C, et al. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clnical trial. Vaccine 2013; 31:1340-1348.
54. Palmer M. The family of thiol-activated, cholesterol-binding cytolysins. Toxicon 2001; 39:1681-1689.
55. Decatur AL, Portnoy DA. A PEST-like sequence in listeriolysin O essential for Listeria monocytogenes pathogenicity. Science 2000; 290:992-995.
56. Arbues A, Aguilo JI, Gonzalo-Asensio J, et al. Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. Vaccine 2013; 31:4867-4873.
57. Walker KB, Brennan MJ, Ho MM, et al. The second Geneva Consensus: recommendations for novel live TB vaccines. Vaccine 2010; 28:2259-2270.
58. Cardona PJ. RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis (Edinb) 2006; 86:273-289.
59. Vilaplana C, Gil O, Caceres N, et al. Prophylactic effect of a therapeutic vaccine against TB based on fragments of Mycobacterium tuberculosis. PLoS One 2011; 6:e20404.
60. Katoch K, Singh P, Adhikari T, et al. Potential of Mw as a prophylactic vaccine against pulmonary tuberculosis. Vaccine 2008; 26:1228-1234.
61. Ahsan MJ, Garg SK, Vashishtha B, Sharma P. Tuberculosis vaccines: hopes and hurdles. Infect Disord Drug Targets 2013. [Epub ahead of print]
62. von Reyn CF, Mtei L, Arbeit RD, et al. Prevention of tuberculosis in bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 2010; 24:675-685.
63. Yang XY, Chen QF, Li YP, Wu SM. Mycobacterium vaccae as adjuvant therapy to antituberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis. PLoS One 2011; 6:e23826.
64. Efremenko YV, Butov DA, Prihoda ND, et al. Randomized, placebo-controlled phase II trial of heat-killed Mycobacterium vaccae (Longcom batch) formulated as an oral pill (V7). Hum Vaccin Immunother 2013; 9:1852-1856.
65. de Bruyn G, Garner P. Mycobacterium vaccae immunotherapy for treating tuberculosis. Cochrane Libr 2010; 1:1-17.
66. Butov DA, Efremenko YV, Prihoda ND, et al. Adjunct immune therapy of firstdiagnosed TB, relapsed TB, treatment-failed TB, multidrug-resistant TB and TB/HIV. Immunotherapy 2012; 4:687-695.
67. Butov DA, Efremenko YV, Prihoda ND, et al. Randomized, placebo-controlled Phase II trial of heat-killed Mycobacterium vaccae (Immodulon batch) formulated as an oral pill (V7). Immunotherapy 2013; 5:1047-1054.
68. Moran M, Guzman J, Chapman N, et al. G-Finder. In: Neglected disease research and development: The public divide. Sydney, Australia: Policy Cures; 2013: (http://www.policycures.org/downloads/GF-report13-all- web.pdf).
69. Rustomjee R, McClain B, Brennan MJ, et al. Designing an adaptive phase II/III trial to evaluate efficacy, safety and immune correlates of new TB vaccines in young adults and adolescents. Tuberculosis (Edinb) 2013; 93:136-142.
70. Rustomjee R, Lockhart S, Shea J, et al. Novel licensure pathways for expeditious introduction of new tuberculosis vaccines: a discussion of the adaptive licensure concept. Tuberculosis (Edinb) 2014; 94:178-182.